2022年10月24日乳腺癌文献共享

• 国际肿瘤学杂志. 2022;49(9):513-516.

• HER2低表达乳腺癌研究进展
• www.gjzlx.cn/CN/10.3760/cma.j.cn371439-20220609-00099

• Signal Transduct Target Ther. 2022 Oct 24;7:370. IF: 38.104
• Dysregulated ceramides metabolism by fatty acid 2-hydroxylase exposes a metabolic vulnerability to target cancer metastasis.
• www.nature.com/articles/s41392-022-01199-1

• JAMA Oncol. 2022 Oct 23. IF: 33.006
• Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases: The FAST-01 Nonrandomized Trial.
• www.jamanetwork.com/journals/jamaoncology/fullarticle/2797843

• Nat Commun. 2022 Oct 23;13:6308. IF: 17.694
• Metabolic control of CD47 expression through LAT2-mediated amino acid uptake promotes tumor immune evasion.
• www.nature.com/articles/s41467-022-34064-4

• Nat Commun. 2022 Oct 23;13:6318. IF: 17.694
• A noncanonical function of EIF4E limits ALDH1B1 activity and increases susceptibility to ferroptosis.
• www.nature.com/articles/s41467-022-34096-w

• Nat Commun. 2022 Oct 23;13:6311. IF: 17.694
• Retinoblastoma protein as an intrinsic BRD4 inhibitor modulates small molecule BET inhibitor sensitivity in cancer.
• www.nature.com/articles/s41467-022-34024-y

• Cell Death Dis. 2022 Oct 23;13:895. IF: 9.685
• MMP7 cleavage of amino-terminal CD95 death receptor switches signaling toward non-apoptotic pathways.
• www.nature.com/articles/s41419-022-05352-0

• Cell Biosci. 2022 Oct 22;12(1):176. IF: 9.584
• Tumour-associated macrophages enhance breast cancer malignancy via inducing ZEB1-mediated DNMT1 transcriptional activation.
• www.biomedcentral.com/articles/10.1186/s13578-022-00913-4

• Breast Cancer Res Treat. 2022 Oct 23. IF: 4.624
• Prognosis and effectiveness of chemotherapy for medullary breast carcinoma.
• link.springer.com/article/10.1007/s10549-022-06749-3

• Breast. 2022 Dec 1;66:157-161. IF: 4.254
• Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib.
• www.thebreastonline.com/article/S0960-9776(22)00170-9/fulltext

• Mol Immunol. 2022 Oct 19;152:45-54. IF: 4.174
• Margetuximab and trastuzumab deruxtecan: New generation of anti-HER2 immunotherapeutic agents for breast cancer.
• www.sciencedirect.com/science/article/pii/S0161589022004497